Biocon reaches patent settlement with Genentech on breast cancer drug
In short
Biocon reached a patent settlement pact with Genentech over a breast cancer drug.
The deal lets Biocon launch the biosimilar in the EU and UK from Q1 2027, and in the US from Q3 2028. The full terms and product name were not stated.
What the reporting says
Biocon reached a patent settlement pact with Genentech over a breast cancer drug, with publisher-supplied reporting saying the deal allows biosimilar launches in the EU and UK from Q1 2027 and in the US from Q3 2028. The agreement appears to set market-entry timing for the product. The underlying settlement terms, product name, and financial details were not stated in the available reporting.
Why it matters
Biocon reached a patent settlement pact with Genentech over a breast cancer drug, and the reported terms allow biosimilar launches in the EU and UK from Q1 2027 and in the US from Q3 2028. This matters because the agreement gives Biocon a clearer path to market entry in major regions. The available reporting does not state the product name, financial terms, or any other settlement conditions.